Adverse events (AEs) are any unfavorable medical occurrences temporally associated with the participant's involvement in a clinical trial, whether or not it is considered related to the investigational treatment or participation in the trial. Adverse events include any
Patients enrolled in a clinical trial are asked about any adverse events at each encounter with the clinical trial team (investigator or clinical trial coordinator). An important aspect of a clinical trial is the careful collection and reporting of adverse events. Usually the trial team is asked to assess whether an adverse event is related to the study drug. In addition, clinical trial programs often use standardized search terms from the Medical Dictionary of Regulatory Activities (MedDRA). The results of these objective searches help detect potential adverse events and are provided to regulatory agencies as part of the submission process for drug approval. MedDRA searches may identify safety concerns that have not otherwise been identified during the clinical trial program.
FDA MedWatch allows physicians as well as patients and consumers to report adverse events directly to the U.S. Food and Drug Administration (FDA). FDA MedWatch is for any FDA approved or unapproved prescription or over-the-counter medicine, biological such as blood products, medical device, nutritional product such as infant formula and medical food, cosmetic, food, and beverage, regardless of whether it is part of a clinical trial.
A serious adverse event (SAE) is any adverse event that
A physician caring for a patient who is enrolled in a clinical trial should inform the investigator of an SAE as soon as possible. The investigator is required to report any SAE to the sponsor within 24 hours from the time the investigator learns about the event. In most clinical trials, the sponsor must report the SAE to the regulatory agency. SAE reporting for investigator-initiated trials is carried out according to terms in the contract with the sponsor and may be slightly different from the phase I to IV clinical trial programs.
Breaking the blind usually occurs after all participants have completed the trial and data collection and monitoring have been completed. However, for an individual patient, breaking the blind ("unblinding") can be done if required for proper care of a patient, and the physician caring for the patient can document that it is essential to know what treatment the patient has been receiving. For example, if the patient has become seriously ill and the physician needs to know all treatments the patient has been receiving, the caring physician must contact the clinical trial investigator and request that the blind be broken. In blinded trials, the investigator does not know the treatment assignment, so the request to unblind a participant is usually the decision of the sponsor (eg, pharmaceutical company, U.S. Department of Veterans Affairs [VA], the National Institutes of Health [NIH] other funding agency). Guidance for unblinding is often provided in the trial protocol and the informed consent document.
When a study patient visits a health care practitioner who is not involved in a trial (and may not even be in the same organization as the trial site), communication among the patient, the health care practitioners, and the clinical trial team is important to ensure optimal patient care as well as clinical trial integrity. Practitioners should become familiar with the key elements of the trial. Practitioners can get this information from the patient's consent form or summary card or by contacting the trial study team. Contact information is in the consent form or summary card given to the patient.
GOOD CLINICAL PRACTICEPART 8: ROLES AND RESPONSIBILITIES1. According to GCP, who is responsible for all study-related medical decisions?A. Study CoordinatorB. PharmacistC. Qualified PhysicianD. Phlebotomist 2. The Sponsor is responsible for designating qualified individuals to carry out all stages of the studyprocess, including: End of preview. Want to read the entire page? Upload your study docs or become a Course Hero member to access this document Tags Clinical trial, Good clinical practice, C Principal Investigator, A Study Coordinator |